- Home
- IMUX vs KOSS Comparison
IMUX vs KOSS Comparison
Compare IMUX & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- KOSS
- Stock Information
- Founded
- IMUX 2016
- KOSS 1953
- Country
- IMUX United States
- KOSS United States
- Employees
- IMUX N/A
- KOSS N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- KOSS Consumer Electronics/Appliances
- Sector
- IMUX Health Care
- KOSS Consumer Staples
- Exchange
- IMUX Nasdaq
- KOSS Nasdaq
- Market Cap
- IMUX 67.8M
- KOSS 59.3M
- IPO Year
- IMUX N/A
- KOSS N/A
- Fundamental
- Price
- IMUX $0.81
- KOSS $5.33
- Analyst Decision
- IMUX Strong Buy
- KOSS
- Analyst Count
- IMUX 6
- KOSS 0
- Target Price
- IMUX $11.60
- KOSS N/A
- AVG Volume (30 Days)
- IMUX 1.8M
- KOSS 89.1K
- Earning Date
- IMUX 08-07-2025
- KOSS 08-28-2025
- Dividend Yield
- IMUX N/A
- KOSS N/A
- EPS Growth
- IMUX N/A
- KOSS N/A
- EPS
- IMUX N/A
- KOSS N/A
- Revenue
- IMUX N/A
- KOSS $12,433,361.00
- Revenue This Year
- IMUX N/A
- KOSS N/A
- Revenue Next Year
- IMUX N/A
- KOSS N/A
- P/E Ratio
- IMUX N/A
- KOSS N/A
- Revenue Growth
- IMUX N/A
- KOSS N/A
- 52 Week Low
- IMUX $0.56
- KOSS $4.00
- 52 Week High
- IMUX $2.11
- KOSS $12.89
- Technical
- Relative Strength Index (RSI)
- IMUX 54.61
- KOSS 50.81
- Support Level
- IMUX $0.68
- KOSS $5.12
- Resistance Level
- IMUX $0.83
- KOSS $5.37
- Average True Range (ATR)
- IMUX 0.05
- KOSS 0.27
- MACD
- IMUX 0.02
- KOSS 0.03
- Stochastic Oscillator
- IMUX 89.29
- KOSS 51.46
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.